Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Priscilla Wander

Priscilla Wander

PhD Student
Drug library and CRISPR/Cas9 screens in high-risk pediatric ALL and AML.
Phone +31 (0) 88 972 76 72

As current treatment regimens clearly fail to establish satisfactory clinical outcomes for certain high-risk types of childhood acute leukemia, novel and more effective treatment strategies are urgently needed for these children. Therefore, I performed high-throughput drug library screens (comprising >4000 compounds) on primary leukemic cells derived from patients diagnosed with high-risk types of acute leukemia. The potential of identified “hits” is currently being evaluated and validated using in vitro and in vivo model systems. In parallel, I have performed a CRISPR/Cas9 knock-out screen using a guide RNA library targeting ~480 genes encoding proteins with epigenetic functions in high-risk MLL-rearranged acute lymphoblastic leukemia (ALL) cells. Since MLL-rearranged ALL is largely (if not solely) driven by inappropriate epigenetic events, identified “hits” in our CRISPR/Cas9 library screen mat well represent novel therapeutic targets and should broaden our insights into the biology of this aggressive type of acute leukemia.